文献速递妇科

早期宫颈癌患者按放射外科方案治疗的结局:临床结果与预后因素

Outcome of early stage cervical cancer patients treated according to a radiosurgical approach: Clinical results and prognostic factors.
PubMed 文献 · Gynecol Oncol · 2017-01-15

本研究分析2000至2013年在本机构接受术前近距离放疗后手术的早期IB1-IIA1期宫颈癌伴危险因素患者182例,中位随访5.3年,5年无病生存率为93.6%(95%CI:91.6-95.6%),盆腔淋巴结转移和肿瘤≥3cm与较差无病生存相关,术前近距离放疗是安全有效的选择。

要点

  • 术前近距离放疗后手术的早期宫颈癌患者5年无病生存率为93.6%(95%CI:91.6-95.6%)。
  • 盆腔淋巴结转移(p=0.001)和肿瘤≥3cm(p=0.003)与较差的无病生存相关。
  • 近距离放疗与手术间隔>10周与盆腔外失败风险升高相关(p=0.003)。

核心结论

  • 术前近距离放疗是早期宫颈癌安全有效的选择。

研究设计与样本

  • 分析2000至2013年在本机构因早期IB1-IIA1期浸润性宫颈癌伴危险因素(淋巴血管栓塞和/或肿瘤>2cm)接受近距离放疗的连续患者结局。
  • 治疗包括术前低剂量或脉冲剂量率子宫阴道近距离放疗,6-8周后行根治性子宫切除术/双侧输卵管卵巢切除术加盆腔±腹主动脉旁淋巴结清扫。
  • 有淋巴结转移组织学证据的患者接受术后放化疗。

主要发现

  • 共识别182例患者,子宫切除标本组织学检查显示55例(30.2%)存在肿瘤残留。
  • 1例(0.5%)在宫旁有残留肿瘤细胞。
  • 中位随访5.3年,14例(7.7%)出现肿瘤复发,包括3例(1.6%)局部复发。
  • 5年无病生存率为93.6%(95%CI:91.6-95.6%)。
  • log-rank分析中,淋巴结清扫时存在盆腔淋巴结转移(p=0.001)和肿瘤大小≥3cm(p=0.003)与较差的无病生存相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report clinical results of a multimodal strategy based on preoperative brachytherapy followed with surgery in early stage cervical cancer. MATERIALS/METHODS: The outcome of consecutive patients receiving brachytherapy in our Institution for an early stage IB1-IIA1 invasive cervical cancer with risk factors (lymphovascular embols and/or tumor >2cm) between 2000 and 2013 was analyzed. The treatment consisted of preoperative low dose or pulse dose-rate utero-vaginal brachytherapy followed, 6-8weeks later, by a radical hysterectomy/bilateral salpingo-oophorectomy plus pelvic±para-aortic lymph node dissection. A postoperative chemoradiation was delivered in patients with histological evidence of lymph nodes metastases. RESULTS: 182 patients were identified. Histological examination of hysterectomy specimen showed the presence of a tumor residuum in 55 patients (30.2%). One patient (0.5%) had residual tumor cells in the parametria. With a median follow-up of 5.3years, 14 patients (7.7%) presented tumor relapse, including three (1.6%) local relapses. Five-year disease-free survival (DFS) rate was 93.6% (95%CI: 91.6-95.6%). In log-rank analysis, presence of pelvic nodal metastases at time of lymphadenectomy (p=0.001) and tumor size ≥3cm (p=0.003) correlated with a poorer DFS. Presence of a tumor residuum on hysterectomy specimen correlated with a higher risk of pelvic or para-aortic failure (p=0.035). A time interval>10weeks between brachytherapy and surgery correlated with a higher risk of failure outside the pelvis (p=0.003). Significant postoperative complications were reported in 16 patients (8.8%). All delayed toxicities were mild to moderate. CONCLUSIONS: A preoperative brachytherapy is a safe and effective option in early stage cervical cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Escande A, Gouy S, Mazeron R, et al. Outcome of early stage cervical cancer patients treated according to a radiosurgical approach: Clinical results and prognostic factors. Gynecol Oncol. 2017. PMID: 28095994. doi:10.1016/j.ygyno.2016.12.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。